Long-Term Specified Drug Use-results Survey of Betanis Tablets
NCT01901120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1263
Last updated 2016-11-01
Summary
This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.
Conditions
Interventions
- DRUG
-
Betanis
oral
Sponsors & Collaborators
-
Astellas Pharma Inc
lead INDUSTRY
Principal Investigators
-
Central Contact · Astellas Pharma Inc
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2016-09-30
- Completion
- 2016-09-30
Countries
- Japan
Study Locations
More Related Trials
-
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214 ·Status: COMPLETED ·Phase: PHASE4
-
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03044912 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00689104 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964 ·Status: COMPLETED ·Phase: PHASE3
-
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
NCT04562090 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
NCT04693897 ·Status: UNKNOWN
-
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688 ·Status: COMPLETED ·Phase: PHASE3
-
Post Marketing Survey of Vesicare in Japan
NCT01489709 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
NCT01638000 ·Status: COMPLETED ·Phase: PHASE3
-
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03059134 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
NCT02320773 ·Status: COMPLETED
-
Study of ONO-8577 in Patients With Overactive Bladder
NCT03106623 ·Status: COMPLETED ·Phase: PHASE2
-
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
NCT02981459 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
NCT02211846 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder
NCT00527033 ·Status: COMPLETED ·Phase: PHASE2
-
Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study
NCT05452434 ·Status: UNKNOWN ·Phase: PHASE4
-
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
NCT00658684 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
NCT02138747 ·Status: COMPLETED ·Phase: PHASE4
-
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
NCT02045862 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
NCT02940314 ·Status: COMPLETED ·Phase: PHASE1
-
MIrabegron With oveRACtive bLadder Symptoms in mEn
NCT02361502 ·Status: UNKNOWN ·Phase: PHASE4
-
Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
NCT03251300 ·Status: UNKNOWN ·Phase: PHASE4
-
Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial
NCT05188742 ·Status: UNKNOWN ·Phase: PHASE4
-
Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome
NCT05040984 ·Status: UNKNOWN
-
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
NCT00337090 ·Status: COMPLETED ·Phase: PHASE2